ConductScience.org, home

Paper39239090

Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline.

Haidar G and 8 others. JAC Antimicrob Resist, 2024. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline. Papers, record 39239090. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39239090

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline.
PubMed
Journal
JAC Antimicrob Resist
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
6.81, provisional
iCite
Revised in PubMed
2025-08-17
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Haidar GGhady
2Kline EGEllen G
3Kitsios GDGeorgios D
4Wang XXiaohong
5Kwak EJEun Jeong
6Newbrough AAnthony
7Friday KKelly
8Hughes Kramer KKailey
9Shields RKRyan Khttps://orcid.org/0000-0001-9794-5665

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K23 AI154546NIAID NIH HHSUnited StatesK23AI154546PubMed and NIHNIH RePORTER
R03 HL162655NHLBI NIH HHSUnited StatesR03HL162655PubMedNIH RePORTER

Download CSV of grants

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133970222Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients.Clin Infect Dis2022https://conductscience.org/library/papers/33970222PubMed
234223033Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study.JAC Antimicrob Resist2020https://conductscience.org/library/papers/34223033PubMed
335867524NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35867524PubMed
431828337Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.J Antimicrob Chemother2020https://conductscience.org/library/papers/31828337PubMed
534545787New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria, Switzerland, 2019-2020.Emerg Infect Dis2021https://conductscience.org/library/papers/34545787PubMed
636968951Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.JAC Antimicrob Resist2023https://conductscience.org/library/papers/36968951PubMed
735815680Evolution of β-lactamase-mediated cefiderocol resistance.J Antimicrob Chemother2022https://conductscience.org/library/papers/35815680PubMed
837416757An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance.Open Forum Infect Dis2023https://conductscience.org/library/papers/37416757PubMed
932988825Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/32988825PubMed
1037463564Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.Clin Infect Dis2023https://conductscience.org/library/papers/37463564PubMed
1132464664Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.J Antimicrob Chemother2020https://conductscience.org/library/papers/32464664PubMed
1225634992Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.J Antimicrob Chemother2015https://conductscience.org/library/papers/25634992PubMed
1332427286Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.Clin Infect Dis2021https://conductscience.org/library/papers/32427286PubMed
1428559260
Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam.
Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28559260PubMed
1537610183Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France.Emerg Infect Dis2023https://conductscience.org/library/papers/37610183PubMed
1625022578Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/25022578PubMed
1728381609Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae.J Clin Microbiol2017https://conductscience.org/library/papers/28381609PubMed
1838661186The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?Clin Infect Dis2024https://conductscience.org/library/papers/38661186PubMed
1937250794The upper and lower respiratory tract microbiome in severe aspiration pneumonia.iScience2023https://conductscience.org/library/papers/37250794PubMed
2034618008Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.Clin Infect Dis2022https://conductscience.org/library/papers/34618008PubMed

See all 22 referencesDownload CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
42938727Carbapenemases in Gram-Negative Bacilli: Classification, Detection, Therapeutic Options, and Resistance to Novel Antimicrobials.Antibiotics (Basel)2026https://conductscience.org/library/papers/42938727PubMed
42921071Molecular characterization of carbapenemase-producing Enterobacterales from Peshawar City, Khyber Pakhtunkhwa, Pakistan.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42921071PubMed
42876900The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42876900PubMed
42714383Impact of PBP3 insertions and β-lactamase-encoding genes on the susceptibility of Escherichia coli isolates belonging to high-risk clones against aztreonam-avibactam and comparator agents.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42714383PubMed
42593110Outbreak of aztreonam-avibactam-resistant NDM-5-producing Escherichia coli isolates in a hospital of Paris.Microbiol Spectr2026https://conductscience.org/library/papers/42593110PubMed
42191848Aztreonam-avibactam at the frontline: A dual-agent approach to metallo-β-lactamase resistance.J Antibiot (Tokyo)2026https://conductscience.org/library/papers/42191848PubMed
42041376Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel)2026https://conductscience.org/library/papers/42041376PubMed
41972762Beneficial impact of acquired AmpC β-lactamases on bacterial fitness and pathogenicity: a new paradigm.mBio2026https://conductscience.org/library/papers/41972762PubMed
41891866
Comparative in vitro efficacy of aztreonam-avibactam and other alternatives (cefepime-taniborbactam, cefepime-zidebactam, and cefiderocol) against metallo-β-lactamase-producing Enterobacterales isolated in 2024 in France.
Antimicrob Agents Chemother2026https://conductscience.org/library/papers/41891866PubMed
41837290The bug, the burden, and the biology: beyond host-centric phenotyping in sepsis.J Clin Invest2026https://conductscience.org/library/papers/41837290PubMed
41805189Comparison of agar-based methodologies to broth disc elution for the detection of aztreonam susceptibility in the presence of ceftazidime-avibactam.Microbiol Spectr2026https://conductscience.org/library/papers/41805189PubMed
41705828
In vitro activity of aztreonam-avibactam and distribution of carbapenemase genes in ceftazidime-avibactam-resistant carbapenem-resistant Enterobacterales: data from the global Antimicrobial Testing Leadership and Surveillance, 2019-2023.
Antimicrob Agents Chemother2026https://conductscience.org/library/papers/41705828PubMed
41665356High in vitro activity of aztreonam/avibactam against NDM-producing Enterobacterales with emerging resistance in Escherichia coli in the United States Mid-Atlantic region.Microbiol Spectr2026https://conductscience.org/library/papers/41665356PubMed
41608681Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Front Microbiol2025https://conductscience.org/library/papers/41608681PubMed
41577890Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions.Eur J Clin Microbiol Infect Dis2026https://conductscience.org/library/papers/41577890PubMed
41522717Management of infections caused by carbapenemase-producing Enterobacterales in France: a real-world study.JAC Antimicrob Resist2026https://conductscience.org/library/papers/41522717PubMed
41455885Genomic characterization and comparative analysis of multidrug-resistant Escherichia coli ST361 from urban wetland.BMC Microbiol2025https://conductscience.org/library/papers/41455885PubMed
41301604Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae.Antibiotics (Basel)2025https://conductscience.org/library/papers/41301604PubMed
41032192NDM-5 and siderophore receptor mutations drive high-level cefiderocol resistance in Klebsiella pneumoniae: a case series.Infection2026https://conductscience.org/library/papers/41032192PubMed
40724005Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing Enterobacterales: Insights from Comparative Genomics.Antibiotics (Basel)2025https://conductscience.org/library/papers/40724005PubMed

See all 24 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39239090

GET https://conductscience.org/api/papers/v1/39239090/references?page=2